Completed PHASE2 INTERVENTIONAL 2-arm NCT00543049

Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor

Phase II Trial in Platinum-refractory Ovarian Cancer: A Randomized Multicenter Trial With SU11248 to Evaluate Dosage, Tolerability, Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor Monotherapy

Sponsor: AGO Study Group

Conditions Cancer of the Fallopian Tube Platinum Refractory Epithelial Ovarian Cancer Primary Cancer of the Peritoneum

Interventions SUNITINIB Sunitinib

Updated 7 times since 2017 Last updated: Mar 6, 2014 Started: Sep 30, 2007 Primary completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cancer of the Fallopian Tube and Platinum Refractory Epithelial Ovarian Cancer, this trial is completed. The trial is conducted by AGO Study Group and has accumulated 7 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Dec 2024 — Sep 2025 [monthly]

Completed PHASE2
Sep 2024 — Dec 2024 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AGO Study Group
HSK Reasearch GmbH Wiesbaden
Philipps University Marburg

Data source: AGO Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bonn, Germany , Bremen, Germany , Dresden, Germany , Essen, Germany , Frankfurt am Main, Germany , Freiburg im Breisgau, Germany , Greifswald, Germany , Hanover, Germany , Karlsruhe, Germany , Kiel, Germany and 6 more locations